Zummo Jacqueline 4

What Happened
Jacqueline Zummo, Chief Scientific Operations Officer at Protara Therapeutics (TARA), received equity awards on January 16, 2026 totaling 210,000 restricted stock units (RSUs). The filing reports two grants: 30,000 RSUs (reported as an acquisition at $0.00 per share) and 180,000 RSUs (reported as a derivative acquisition at $0.00 per share). These are awards—no cash changed hands and no open‑market purchase or sale occurred.

Key Details

• Transaction date: 2026-01-16; Filing date: 2026-01-21 (filed five days after the transaction). Form 4s for insiders are typically due within 2 business days.
• Grants reported: 30,000 RSUs @ $0.00 (acquired) and 180,000 RSUs @ $0.00 (derivative). Total = 210,000 RSUs.
• Reported value at grant: $0 immediate cash value (standard for RSU awards; future value depends on stock price at vesting).
• Shares owned after transaction: not specified in the provided filing.
• Vesting/footnotes:
  • 30,000 RSUs: vest in equal one‑third installments on the 1st, 2nd and 3rd anniversaries of Jan 16, 2026, subject to continued service.
  • 180,000 RSUs: 25% vests on the one‑year anniversary of Jan 16, 2026, then 1/48th vests monthly thereafter over the next three years, subject to continued service.

Context
RSU grants are common executive compensation and do not indicate an immediate buy or sell signal; they represent a contingent right to receive shares if vesting conditions are met. The filing shows award grants rather than purchases—purchases are often seen as a stronger bullish indicator. The later filing date (Jan 21 vs. transaction Jan 16) may be a timeliness issue; investors tracking insider reporting should note the lag.